Maddox Pharma Swiss Revenue and Competitors

Zug, Switzerland

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Maddox Pharma Swiss's estimated annual revenue is currently $21.3M per year.(i)
  • Maddox Pharma Swiss's estimated revenue per employee is $201,000

Employee Data

  • Maddox Pharma Swiss has 106 Employees.(i)
  • Maddox Pharma Swiss grew their employee count by 15% last year.

Maddox Pharma Swiss's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.5M522%N/AN/A
#2
$155.6M7747%N/AN/A
#3
$40.8M20310%N/AN/A
#4
$245.6M1222-24%N/AN/A
#5
$142.3M7080%N/AN/A
#6
$141.1M702-9%N/AN/A
#7
$16.7M8328%N/AN/A
#8
$16.5M828%N/AN/A
#9
$21.3M10615%N/AN/A
#10
$13.7M68-1%N/AN/A
Add Company

What Is Maddox Pharma Swiss?

Maddox Pharma Swiss is a European Pharmaceutical Company, was established in 2015, specialized in both Pharmaceuticals and Food supplements. Maddox Pharma Swiss supplies high-quality products across the global markets. Our mission is to enhance people's health and quality of life by providing a rich product portfolio and services that match their needs. In Maddox Pharma Swiss, we are continuously consolidating our position as a leading supplier of generic pharmaceuticals as well as food supplements worldwide. We aim to achieve this by strengthening the long-term relationship with all the stakeholders in terms of development, product supply, and marketing of value-added products and services. Our Values • Act with honesty as we believe in our responsibility towards our customers. • Value our customers and their needs. • Committed to improve efficiency with the highest standards of performance to achieve our goals. • Operate clearly and openly, to ease others to observe our performance.

keywords:N/A

N/A

Total Funding

106

Number of Employees

$21.3M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21.3M10615%N/A
#2
N/A1129%N/A
#3
$10.5M11320%N/A
#4
$17.4M11614%N/A
#5
$25.5M1165%N/A